Literature DB >> 29682512

Targeting Notch signalling pathway of cancer stem cells.

Vandana Venkatesh1, Raghu Nataraj2, Gopenath S Thangaraj3, Murugesan Karthikeyan4, Ashok Gnanasekaran4, Shanmukhappa B Kaginelli5, Gobianand Kuppanna6, Chandrashekrappa Gowdru Kallappa7, Kanthesh M Basalingappa1.   

Abstract

Cancer stem cells (CSCs) have been defined as cells within tumor that possess the capacity to self-renew and to cause the heterogeneous lineages of cancer cells that comprise the tumor. CSCs have been increasingly identified in blood cancer, prostate, ovarian, lung, melanoma, pancreatic, colon, brain and many more malignancies. CSCs have slow growth rate and are resistant to chemotherapy and radiotherapy that lead to the failure of traditional current therapy. Eradicating the CSCs and recurrence, is promising aspect for the cure of cancer. The CSCs like any other stem cells activate the signal transduction pathways that involve the development and tissue homeostasis, which include Notch signaling pathway. The new treatment targets these pathway that control stem-cell replication, survival and differentiation that are under development. Notch inhibitors either single or in combination with chemotherapy drugs have been developed to treat cancer and its recurrence. This approach of targeting signaling pathway of CSCs represents a promising future direction for the therapeutic strategy to cure cancer.

Entities:  

Keywords:  Cancer stem cells (CSC); Notch intracellular domain (NICD); Notch signaling pathway; angiogenesis; delta like ligand 4 (DLL-4); epithelial-mesenchymal transition (EMT); metastasis; monoclonal antibodies (mAb); γ-secretase inhibitors (GSIs)

Year:  2018        PMID: 29682512      PMCID: PMC5897708          DOI: 10.21037/sci.2018.02.02

Source DB:  PubMed          Journal:  Stem Cell Investig        ISSN: 2306-9759


  55 in total

1.  Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency.

Authors:  Wan-Ching Yen; Marcus M Fischer; Fumiko Axelrod; Christopher Bond; Jennifer Cain; Belinda Cancilla; William R Henner; Rene Meisner; Aaron Sato; Jalpa Shah; Tracy Tang; Breanna Wallace; Min Wang; Chun Zhang; Ann M Kapoun; John Lewicki; Austin Gurney; Timothy Hoey
Journal:  Clin Cancer Res       Date:  2015-05-01       Impact factor: 12.531

2.  Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models.

Authors:  Cathy C Zhang; Adam Pavlicek; Qin Zhang; Maruja E Lira; Cory L Painter; Zhengming Yan; Xianxian Zheng; Nathan V Lee; Mark Ozeck; Ming Qiu; Qing Zong; Patrick B Lappin; Anthony Wong; Paul A Rejto; Tod Smeal; James G Christensen
Journal:  Clin Cancer Res       Date:  2012-07-17       Impact factor: 12.531

3.  γ-Secretase inhibitor reduces immunosuppressive cells and enhances tumour immunity in head and neck squamous cell carcinoma.

Authors:  Liang Mao; Zhi-Li Zhao; Guang-Tao Yu; Lei Wu; Wei-Wei Deng; Yi-Cun Li; Jian-Feng Liu; Lin-Lin Bu; Bing Liu; Ashok B Kulkarni; Wen-Feng Zhang; Lu Zhang; Zhi-Jun Sun
Journal:  Int J Cancer       Date:  2017-11-02       Impact factor: 7.396

4.  Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors.

Authors:  Ian Krop; Tim Demuth; Tina Guthrie; Patrick Y Wen; Warren P Mason; Prakash Chinnaiyan; Nicholas Butowski; Morris D Groves; Santosh Kesari; Steven J Freedman; Samuel Blackman; James Watters; Andrey Loboda; Alexei Podtelezhnikov; Jared Lunceford; Cong Chen; Maxine Giannotti; Jeremy Hing; Robert Beckman; Patricia Lorusso
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

5.  The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models.

Authors:  Masamichi Mizuma; Zeshaan A Rasheed; Shinichi Yabuuchi; Noriyuki Omura; Nathaniel R Campbell; Roeland F de Wilde; Elizabeth De Oliveira; Qing Zhang; Oscar Puig; William Matsui; Manuel Hidalgo; Anirban Maitra; N V Rajeshkumar
Journal:  Mol Cancer Ther       Date:  2012-07-02       Impact factor: 6.261

Review 6.  The Notch signaling pathway as a mediator of tumor survival.

Authors:  Kathleen M Capaccione; Sharon R Pine
Journal:  Carcinogenesis       Date:  2013-04-12       Impact factor: 4.944

Review 7.  Rational targeting of Notch signaling in cancer.

Authors:  P Rizzo; C Osipo; K Foreman; T Golde; B Osborne; L Miele
Journal:  Oncogene       Date:  2008-09-01       Impact factor: 9.867

8.  A phase II study of RO4929097 in metastatic colorectal cancer.

Authors:  Jonathan R Strosberg; Timothy Yeatman; Jill Weber; Domenico Coppola; Michael J Schell; Gang Han; Khaldoun Almhanna; Richard Kim; Tiffany Valone; Helen Jump; Dan Sullivan
Journal:  Eur J Cancer       Date:  2012-03-23       Impact factor: 9.162

9.  Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer.

Authors:  Marzia A Locatelli; Philippe Aftimos; E Claire Dees; Patricia M LoRusso; Mark D Pegram; Ahmad Awada; Bo Huang; Rossano Cesari; Yuqiu Jiang; M Naveed Shaik; Kenneth A Kern; Giuseppe Curigliano
Journal:  Oncotarget       Date:  2017-01-10

10.  A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma.

Authors:  Ana De Jesus-Acosta; Daniel Laheru; Anirban Maitra; John Arcaroli; Michelle A Rudek; Arvind Dasari; Patrick J Blatchford; Kevin Quackenbush; Wells Messersmith
Journal:  Invest New Drugs       Date:  2014-03-27       Impact factor: 3.850

View more
  74 in total

1.  DAPT, a potent Notch inhibitor regresses actively growing abdominal aortic aneurysm via divergent pathways.

Authors:  Chetan P Hans; Neekun Sharma; Rishabh Dev; Jones M Blain; Jeff Tonniges; Gunjan Agarwal
Journal:  Clin Sci (Lond)       Date:  2020-06-26       Impact factor: 6.124

2.  Targeting of Lung Cancer Stem Cell Self-Renewal Pathway by a Small Molecule Verrucarin J.

Authors:  Karen Udoh; Seema Parte; Kelsey Carter; Aaron Mack; Sham S Kakar
Journal:  Stem Cell Rev Rep       Date:  2019-08       Impact factor: 5.739

3.  NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells.

Authors:  Elia Farah; Chaohao Li; Lijun Cheng; Yifan Kong; Nadia A Lanman; Pete Pascuzzi; Gabrielle Renee Lorenz; Yanquan Zhang; Nihal Ahmad; Lang Li; Tim Ratliff; Xiaoqi Liu
Journal:  J Biol Chem       Date:  2019-04-02       Impact factor: 5.157

Review 4.  Cancer stem cells and nanotechnological approaches for eradication.

Authors:  Gholam Basati; Mojtaba Khaksarian; Saber Abbaszadeh; Hamed Esmaeil Lashgarian; Abdolrazagh Marzban
Journal:  Stem Cell Investig       Date:  2019-11-28

5.  PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition.

Authors:  Vaishnavi Sambandam; Mitchell J Frederick; Li Shen; Pan Tong; Xiayu Rao; Shaohua Peng; Ratnakar Singh; Tuhina Mazumdar; Chenfei Huang; Qiuli Li; Curtis R Pickering; Jeffery N Myers; Jing Wang; Faye M Johnson
Journal:  Clin Cancer Res       Date:  2019-02-15       Impact factor: 12.531

Review 6.  Cancer stem cells in breast and prostate: Fact or fiction?

Authors:  Rocío G Sampayo; Mina J Bissell
Journal:  Adv Cancer Res       Date:  2019-06-13       Impact factor: 6.242

Review 7.  Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments.

Authors:  Xiaoxu Wei; Yunhua Chen; Xianjie Jiang; Miao Peng; Yiduo Liu; Yongzhen Mo; Daixi Ren; Yuze Hua; Boyao Yu; Yujuan Zhou; Qianjin Liao; Hui Wang; Bo Xiang; Ming Zhou; Xiaoling Li; Guiyuan Li; Yong Li; Wei Xiong; Zhaoyang Zeng
Journal:  Mol Cancer       Date:  2021-01-04       Impact factor: 27.401

Review 8.  Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update.

Authors:  Joseph A Clara; Cecilia Monge; Yingzi Yang; Naoko Takebe
Journal:  Nat Rev Clin Oncol       Date:  2019-12-02       Impact factor: 66.675

9.  Glioblastoma Stem Cell-Derived Exosomes Enhance Stemness and Tumorigenicity of Glioma Cells by Transferring Notch1 Protein.

Authors:  Zhen Sun; Li Wang; Yueling Zhou; Lihua Dong; Weichao Ma; Liang Lv; Jie Zhang; Xiujie Wang
Journal:  Cell Mol Neurobiol       Date:  2019-12-18       Impact factor: 5.046

10.  ABL1, Overexpressed in Hepatocellular Carcinomas, Regulates Expression of NOTCH1 and Promotes Development of Liver Tumors in Mice.

Authors:  Fang Wang; Wei Hou; Lennox Chitsike; Yingchen Xu; Carlee Bettler; Aldeb Perera; Thomas Bank; Scott J Cotler; Asha Dhanarajan; Mitchell F Denning; Xianzhong Ding; Peter Breslin; Wenan Qiang; Jun Li; Anthony J Koleske; Wei Qiu
Journal:  Gastroenterology       Date:  2020-06-24       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.